These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 27662324)
1. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations. Yang HS Cancer Biomark; 2016; 17(4):383-389. PubMed ID: 27662324 [TBL] [Abstract][Full Text] [Related]
2. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR. Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting. Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531 [TBL] [Abstract][Full Text] [Related]
5. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation. Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681 [TBL] [Abstract][Full Text] [Related]
6. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance]. Tang Q; Zhang XW; Xia L; Jiang NK Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393 [TBL] [Abstract][Full Text] [Related]
7. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients. Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773 [TBL] [Abstract][Full Text] [Related]
9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
10. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C; J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676 [TBL] [Abstract][Full Text] [Related]
11. Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ha JS; Kim YK Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276 [TBL] [Abstract][Full Text] [Related]
12. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms. Belcic Mikic T; Pajic T; Sever M Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869 [TBL] [Abstract][Full Text] [Related]
13. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms. Martin S; Wright CM; Scott LM Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700 [TBL] [Abstract][Full Text] [Related]
14. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms. Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170 [TBL] [Abstract][Full Text] [Related]
15. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion. Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and phenotypes of Cordua S; Kjaer L; Skov V; Pallisgaard N; Hasselbalch HC; Ellervik C Blood; 2019 Aug; 134(5):469-479. PubMed ID: 31217187 [TBL] [Abstract][Full Text] [Related]
17. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia. Haage TR; Charakopoulos E; Bhuria V; Baldauf CK; Korthals M; Handschuh J; Müller P; Li J; Harit K; Nishanth G; Frey S; Böttcher M; Fischer KD; Dudeck J; Dudeck A; Lipka DB; Schraven B; Green AR; Müller AJ; Mougiakakos D; Fischer T J Hematol Oncol; 2024 Jun; 17(1):43. PubMed ID: 38853260 [TBL] [Abstract][Full Text] [Related]
18. Pitfalls of using polymerase chain reaction-based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile! Krishnamurthy K; Chai J; Wang Y; Naeem R; Goldstein DY Am J Clin Pathol; 2024 Feb; 161(2):155-161. PubMed ID: 37788380 [TBL] [Abstract][Full Text] [Related]
19. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations. Turakhia SK; Murugesan G; Cotta CV; Theil KS J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830 [TBL] [Abstract][Full Text] [Related]